Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2008-11-06 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA, société biopharmaceutique qui développe des médicaments ciblant le système immunitaire inné, annonce un chiffre d’affaires de 5,9 millions d’euros pour la période du 1er janvier au 3
Earnings Release Classification · 99% confidence The document is titled "INNATE PHARMA ANNONCE UN CHIFFRE D'AFFAIRES DE 5,9 MILLIONS D'EUROS POUR LES NEUF PREMIERS MOIS DE 2008" (Innate Pharma announces revenues of 5.9 million euros for the first nine months of 2008). It provides key financial highlights (revenue figures for the nine-month period ending September 30, 2008, and Q3 figures) and a brief cash position update. This structure—a press release announcing key financial metrics for a specific period without the full detail of a comprehensive report (like a 10-K or a full IR)—is characteristic of an Earnings Release (ER). It is not a full Interim Report (IR) as it only provides highlights and cash position, not a full set of financial statements and management discussion and analysis (MDA). It is also not a Report Publication Announcement (RPA) because it contains the actual results, not just an announcement that results are forthcoming. 9M 2008
2008-11-06 French
Innate Pharma SA, a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announces a turnover of 5.9 million euros for the first nine months of 2008
Earnings Release Classification · 99% confidence The document is titled "INNATE PHARMA ANNOUNCES 5.9 MILLION EUROS IN TURNOVER FOR THE FIRST NINE MONTHS OF 2008" and provides key financial figures (turnover, cash position) for a specific interim period (nine months ending September 30, 2008). This structure—a brief announcement highlighting key performance indicators for a period shorter than a full year—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). It is the initial announcement of period results. 9M 2008
2008-11-06 English
Innate Pharma SA annonce que le rationnel pré-clinique de l’immunothérapie ciblant les lymphocytes T gamma-delta dans l’hépatite virale de type C est décrit dans un poster présenté aujourd’hui lors du
Earnings Release Classification · 95% confidence The document is a press release dated November 4, 2008, announcing that Innate Pharma is presenting pre-clinical rationale for a T-cell immunotherapy in Hepatitis C at the AASLD congress. It details ongoing clinical trials (Phase IIa for IPH 1101) and provides background on the drug candidates and the disease. This format—a news announcement detailing scientific progress, clinical trial updates, and corporate information, often released to the public and investors—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full annual report (10-K), a formal quarterly report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), it best fits the 'Earnings Release' category, which covers initial announcements of key periodic results or significant corporate/scientific milestones intended for the market. Given the focus on scientific presentation and trial updates, it is a significant corporate announcement, aligning closely with the function of an ER, even if it's not strictly quarterly earnings figures. It is not a Report Publication Announcement (RPA) because it contains substantial original content about the science and trials, not just a notice that a report is available. 9M 2008
2008-11-04 French
Innate Pharma S.A. announces today that the preclinical rationale of the gamma-delta T cell immunotherapy in type-C viral hepatitis was presented today at the AASLD Annual Meeting in San Francisco, U
Regulatory Filings Classification · 90% confidence The document is a press release dated November 4, 2008, announcing that preclinical rationale for a gamma-delta T cell immunotherapy in Type C Viral Hepatitis was presented at the AASLD Annual Meeting. It details scientific findings, ongoing clinical trials (Phase IIa), and provides background information on the drug candidates (IPH 1101 and IPH 1201) and the disease. This structure—announcing scientific data presentation, providing clinical updates, and including company/disclaimer boilerplate—is characteristic of an Earnings Release (ER) or a general corporate update, but since it focuses heavily on scientific/clinical progress rather than just financial results highlights, it fits best as a general corporate announcement that is not a formal regulatory filing like a 10-K or IR. Given the options, it is a press release announcing scientific progress, which often overlaps with an Earnings Release (ER) if it contains key operational updates, or could be considered a Regulatory Filing (RNS) if it doesn't fit elsewhere. However, the content is a detailed announcement of scientific data presentation and trial progress, which is a common component of an Earnings Release or a general corporate update. Since it is not a transcript (CT), a formal report (10-K, IR), or a specific financing/dividend notice, and it is a substantial announcement, 'ER' (Earnings Release, often used for major operational/scientific announcements) is the closest fit among the specific options, although 'RNS' (Regulatory Filings/General Announcement) is also plausible. Given the focus on presenting data at a major meeting, it functions as a significant operational/scientific update, leaning towards ER.
2008-11-04 English
Innate Pharma SA, société biopharmaceutique qui développe des médicaments ciblant le système immunitaire inné, annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés F
Report Publication Announcement Classification · 99% confidence The document is a short announcement (2881 characters) titled "INNATE PHARMA ANNONCE la mise à disposition de son rapport semestriel au 30 juin 2008" (Innate Pharma announces the availability of its semi-annual report as of June 30, 2008). It explicitly states that the 'Rapport semestriel' (Semi-annual report) has been made available to the public and filed with the AMF, and provides a link to download it. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). The content is not a full Interim Report (IR) or Annual Report (10-K), but rather the notice of its release.
2008-10-20 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.